Table 1

Behavioural and psychosocial characteristics and baseline demographic variables of daily PrEP users

Total (n=257)
N%*
Demographic characteristics
 Age (years)
  Median (IQR)39(32–48)
 Age (years; categorised)
  ≤348533
  35–448031
  ≥459236
 Gender identity
  Male25699
  Transgender woman11
 Self-declared ethnicity
  White21784
  Non-white4016
 Place of residency in the Netherlands
  Amsterdam15962
  Other9838
 Education level
  No college/University6425
  College/University19375
 Employment†
  Employed20280
  Unemployed94
  Other (retired, volunteer, disabled, student)4317
 Net monthly income in €‡
  ≤17006627
  1701–295010342
  >29507430
 Living situation
  Alone14155
  With partner8132
  With parents/Flatmates3514
 Steady relationship§
  No14356
  Yes11144
 Sexual preference¶
  Exclusively homosexual19978
  Not exclusively homosexual5722
Sexual behaviour
 Number of sex partners**
  Median (IQR)15(8–32)
 Number of condomless anal sex episodes with casual partners**
  Median (IQR)6(3–15)
 STIs††
  No15861
  Yes9939
 Condomless anal sex with a casual partner (6 months prior to inclusion in AMPrEP)
  No135
  Yes24495
Mental health characteristics and drug use
 Sexual compulsivity scale
  Score <24 (no indication of sexual compulsivity)19676
  Score ≥24 (indication of sexual compulsivity)6124
 Chemsex‡‡
  No14758
  Yes10642
 Depression or anxiety symptoms
  MHI-5 score ≥60 (no symptoms)21282
  MHI-5 score <60 (symptoms)4518
 Alcohol Use Disorder Identification Test§
  Score <8 (no indication)18673
  Score ≥8 (indication)6827
 Drug Use Disorder Identification Test
  Score <8 (no indication)16062
  Score ≥8 (indication)9738
 Level of concern about acquiring HIV§§
  Low4116
  Neutral to high21684
 Level of importance to prevent HIV§§
  Very unimportant to important7027
  Very important18773
Access to mobile application
 Standard app15259
 Extended app10541
AMPrEP study visit attendance
 12 months24696
 24 months21584
  • AMPrEP study, Amsterdam, 2015–2018.

  • *Percentages may not total 100 due to rounding.

  • †3 missing.

  • ‡14 missing.

  • §3 missing.

  • ¶1 missing.

  • **In the 3 months prior to inclusion into AMPrEP.

  • ††Chlamydia, gonorrhoea and/or syphilis within 6 months prior to inclusion into AMPrEP.

  • ‡‡Use of γ-hydroxybutyrate, γ-butyrolactone, methamphetamine or mephedrone prior to or during sex in the 3 months prior to inclusion into AMPrEP, 4 missing.

  • §§Scale 1–7, dichotomised.

  • AMPrEP, Amsterdam PrEP demonstration project; MHI5, Mental Health Inventory-5; PrEP, pre-exposure prophylaxis; RCT, randomised clinical trial.